How Not to Ruin a Perfectly Good Product With a Flawed Study Design

Quantity Discounts
1 - 9999
1 - 9999
1 - 9999
1 - 9999
58% of Phase III trials fail. Why?

Sometimes that’s because the product is ineffective.  But more often than not it’s because of poor study design or implementation.

Nearly every day, the newswires burn up with articles about high-profile products that are scrapped by their sponsors.

Or, FDA complete response letters are issued that require sponsors to go back and repeat or revise their clinical trials. Both equate to millions of dollars of time and effort down the drain.

SPECIAL BONUS for Attendees

Attendees will receive a comprehensive side-by-side matrix table comparing study design guidelines for drugs, biologics and devices. These guidelines include: ICH E6/E8, FDA CFR 312, FDA CFR 812 and ISO 14155:2011 (Annex A). The matrix table identifies requirements within 89 specific sections of the regulations.

Register Today

Attendees will receive practical and easy-to-use information that will guarantee further understanding of study design and aid in approvability of an investigational product.

Join Dr. Debbie Wilkerson for a 90-minute encore presentation guiding you through examples of recognized study design guidances and best practices from correct and incorrect drug and device case studies. Don’t ruin a perfectly good product with a perfectly flawed study design.

Attendees will learn:

  • How to design a valid study that satisfies the FDA and product development endpoints
  • Top 5 key issues that need to be addressed when designing a valid study
  • Real-world scenarios analyzed as to why some investigational products don’t get approved
  • How to tell if there are issues within an already-designed study — the answers will surprise you
This encore presentation is intended for both sponsors and sites in the drug and medical device industries.

Register now.

Participants include everyone who is a key player in designing and managing FDA clinical trials, including:

  • Clinical Research Directors and Study Designers
  • Medical Directors
  • Subject Matter Experts
  • Compliance Officials
  • Regulatory Managers

Dr. Debbie Wilkerson, Clinical Research Director, Medtronic Spinal.
Dr. Wilkerson oversees clinical development plans, including clinical study designs, for biologics/devices. Her responsibilities include working cross-functionally on clinical trials to ensures on-time implementation and delivery. Dr. Wilkerson’s industry experience has been primarily focused in clinical operations, overlapping with regulatory affairs, drug packaging and labeling, product development, data management and pharmacovigilance. Dr. Wilkerson earned her PhD in biochemistry from the Stanford University School of Medicine.

Register now!

Date: Nov. 19 - Dec. 7, 2012 
Location: Your office or conference room (no need to travel!)
Time: Anytime

Gather your team for maximum benefit! Your investment is for one dial-in.

Interested in registering multiple sites?

Significant tuition discounts are available for three or more sites from
the same company. You must register at the same time and
provide a single payment to take advantage of the discount. Register below
by clicking on add to cart and then change your quantity in the shopping cart.
The discount will be calculated automatically.

3-4 sites – 10%
7-9 sites – 20%
5-6 sites – 15%
10+ sites – 25%

Call (888) 838-5578 in the U.S. or +1 (703) 538-7600 globally
with any questions.

We accept American Express, Visa and MasterCard. Make checks payable to FDAnews.

Or, register by phone: toll free (888) 838-5578 (inside the U.S.) or +1 (703) 538-7600

Registrations may not be cancelled. Please contact customer service to make any substitutions.